Study of hypoglycemic activity of tablets of “Gliphasonorm” capsules and “Gliphasolin” on the model of streptozotocin-induced diabetes in rats

Abstract

<p>The conducted research allowed to determine that the tablets “Gliphasonorm” capsules and “Gliphasolin” in an<br />experimental model of streptozotocin-induced diabetes significantly reduced the level of glycosylated hemoglobin,<br />decreased with the level of glucose in the blood of animals compared to diabetic control. After 14 days of the study<br />capsules “Gliphasolin” showed a more pronounced hypoglycemic activity (4.4 % and 8.0 % greater) than tablets<br />“Gliphasonorm” and the reference drug metformin. Under the action caps “Gliphasolin” on the 12th day of the study<br />showed marked reduction of glycosylated hemoglobin in the blood of animals (3.1 % and 5.6 % greater) than that of<br />the tablets of “Gliphasonorm” and metformin. Capsules “Gliphasolin” and tablets “Gliphasonorm” based bioflavonoid<br />complex from beans are promising in the therapy of diabetes type 2 on the background of obesity and reduce the<br />risk of micro- and macroangiopathies.</p>